Valneva SE (VALN) Change in Working Capital (2021 - 2026)
Valneva SE's (VALN) quarterly Change in Working Capital came in at $20.2 million in Q1 2026, up 308.94% year-on-year from $4.9 million in Q1 2025, and up 16442.61% quarter-over-quarter from -$123388.6 in Q4 2025.
Valneva SE (VALN) Change in Working Capital (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Change in Working Capital across 6 years of filings, most recently posting $20.2 million for Q1 2026.
- Change in Working Capital for Q1 2026 came in at $20.2 million, up 308.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.6 million (up 134.03% YoY), and the FY2025 annual result was $1.7 million, down 85.94% from the prior year.
- Change in Working Capital came in at $20.2 million for Q1 2026 at Valneva SE, up from -$123388.6 in the prior quarter.
- In the past five years, Change in Working Capital ranged from a high of $46.5 billion in Q3 2023 to a low of -$46.6 billion in Q2 2023.
- The 5-year median for Change in Working Capital is -$123388.6 (2025), against an average of $10.8 million.
- Peak annual rise in Change in Working Capital reached 41843.2% in 2023, while the deepest fall reached 29580.84% in 2023.
- Valneva SE's Change in Working Capital stood at -$51.6 million in 2022, then soared by 598.31% to $257.1 million in 2023, then slumped by 80.68% to $49.7 million in 2024, then plunged by 100.25% to -$123388.6 in 2025, then jumped by 16442.61% to $20.2 million in 2026.
- The last three Change in Working Capital figures came in at $20.2 million (Q1 2026), -$123388.6 (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Working Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 20.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.16 Mn |
| Mar 31, 2026 | 20.16 Mn |
| Dec 31, 2025 | -123,388.61 |
| Dec 31, 2025 | -123,388.61 |
| Sep 30, 2025 | 10.95 Mn |
| Sep 30, 2025 | 10.95 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | -9.65 Mn |
| Mar 31, 2025 | -9.65 Mn |
| Dec 31, 2024 | 49.66 Mn |
| Dec 31, 2024 | 49.66 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Sep 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -21.79 Mn |
| Jun 30, 2024 | -21.79 Mn |
| Mar 31, 2024 | -11.87 Mn |
| Mar 31, 2024 | -11.87 Mn |
| Dec 31, 2023 | 257.06 Mn |
| Dec 31, 2023 | 257.06 Mn |